Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2020 | 12-2019 | 12-2018 | 12-2017 | |
| Sales | 0 | 294,013 | 298,853 | 284,924 | 315,917 |
| Cost of Goods | N/A | N/A | N/A | N/A | 68,155 |
| Gross Profit | N/A | 294,013 | 298,853 | 284,924 | 247,762 |
| Operating Expenses | 0 | 144,722 | 159,236 | 134,868 | 149,466 |
| Operating Income | N/A | 149,291 | 139,617 | 150,056 | 98,451 |
| Interest Expense | 0 | 61,565 | 79,174 | 62,573 | 41,815 |
| Other Income | 0 | -5,484 | -313 | -677 | -765 |
| Pre-tax Income | 0 | 82,242 | 60,130 | 86,806 | 55,871 |
| Income Tax | N/A | 1,800 | 4,783 | 5,089 | -6,694 |
| Net Income Continuous | N/A | 80,442 | 55,347 | 81,717 | 62,565 |
| Net Income Discontinuous | N/A | -52,709 | -24,336 | -3,121 | 9,495 |
| Net Income | $N/A | $27,733 | $31,011 | $78,596 | $72,060 |
| EPS Basic Total Ops | N/A | 1.08 | 1.25 | 3.76 | 3.74 |
| EPS Basic Continuous Ops | N/A | 4.08 | 2.62 | 3.92 | 3.25 |
| EPS Basic Discontinuous Ops | N/A | -3.00 | -1.37 | -0.16 | 0.49 |
| EPS Diluted Total Ops | N/A | 1.06 | 1.23 | 3.71 | 3.68 |
| EPS Diluted Continuous Ops | N/A | 4.03 | 2.58 | 3.86 | 3.19 |
| EPS Diluted Discontinuous Ops | N/A | -2.97 | -1.35 | -0.15 | 0.49 |
| EPS Diluted Before Non-Recurring Items | N/A | 5.06 | 2.34 | 3.64 | 2.87 |
| EBITDA(a) | $N/A | $269,381 | $255,665 | $260,874 | $203,111 |